Oryzon Genomics SA
MAD:ORY

Watchlist Manager
Oryzon Genomics SA Logo
Oryzon Genomics SA
MAD:ORY
Watchlist
Price: 1.558 EUR -0.76% Market Closed
Market Cap: 99.4m EUR
Have any thoughts about
Oryzon Genomics SA?
Write Note

P/E
Price to Earnings

-25.6
Current
-30.1
Median
22.7
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-25.6
=
Market Cap
98.1m EUR
/
Net Income
-3.8m EUR
All Countries
Close
Market Cap P/E
ES
Oryzon Genomics SA
MAD:ORY
98.1m EUR -25.6
FR
Pharnext SCA
OTC:PNEXF
6T USD -181 004.1
US
Abbvie Inc
NYSE:ABBV
312.7B USD 61.5
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 37.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD -242.3
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 891.9
US
Epizyme Inc
F:EPE
94.1B EUR -472
AU
CSL Ltd
ASX:CSL
133.6B AUD 32.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD 17.5
US
Seagen Inc
F:SGT
39.3B EUR -54.6
NL
argenx SE
XBRU:ARGX
34.8B EUR -131
Earnings Growth
ES
Oryzon Genomics SA
MAD:ORY
Average P/E: 208.2
Negative Multiple: -25.6
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -242.3
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -131 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-26.8
2-Years Forward
P/E
-259.6
3-Years Forward
P/E
-20.4

See Also

Discover More